Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions.
about
Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesisMucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growthThe current status of therapeutic HPV vaccineHPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia.Human papillomavirus infections: epidemiology, pathogenesis, and therapy.HPV-mediated cervical carcinogenesis: concepts and clinical implications.The E5 proteinsDifferential expression of HPV16 L2 gene in cervical cancers harboring episomal HPV16 genomes: influence of synonymous and non-coding region variationsGenerating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.Immunosuppressive tumor microenvironment in cervical cancer patientsHuman papillomavirus cervical infection and associated risk factors in a region of Argentina with a high incidence of cervical carcinomaLoss of human leucocyte antigen class I and gain of class II expression are early events in carcinogenesis: clues from a study of Barrett's oesophagus.Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumoursConservation of immune gene signatures in solid tumors and prognostic implications.Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas.LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12.Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions.Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodesThe invisible arm of immunity in common cancer chemoprevention agents.Association of TAP gene polymorphisms and risk of cervical intraepithelial neoplasiaDistribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay.Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases.Major histocompatibility antigens and antigen-processing molecules in retinoblastoma.Analysis of Class I Major Histocompatibility Complex Gene Transcription in Human Tumors Caused by Human Papillomavirus Infection.Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation.Association of -463G/A MPO gene polymorphism and risk of cervical intraepithelial neoplasia.Human papillomavirus type 16 (HPV 16) E7 and major histocompatibility complex (MHC) class I and II expression in human keratinocytes in culture.NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients.Interferon-beta and -gamma, but not tumor necrosis factor-alpha, demonstrate immunoregulatory effects on carcinoma cell lines infected with human papillomavirus.Differential MHC class II component expression in HPV-positive cervical cancer cells: implication for immune surveillance.HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines.MHC class I heavy chain mRNA must exceed a threshold level for the reconstitution of cell surface expression of class I MHC complexes in cells transformed by the highly oncogenic adenovirus 12.Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins.Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesionsHuman papillomavirus E5 oncoprotein: function and potential target for antiviral therapeuticsCervical Local Immune Response for High-Risk Human Papillomavirus Infection: Involvement With Cervical Mucus SLPI Proteins
P2860
Q22253275-A32B6A13-7F76-4F6F-8323-0A7430B6C878Q24559793-0B101BE6-2FEE-4086-9F0A-B76C05D4C611Q28302676-64B2B315-6D1B-47C7-AABC-9F618BA1DB0DQ34138292-831D912F-0EF0-4783-AA0A-EFF97DFF1567Q34204141-4BDF73E2-732C-4342-92AA-C54D076BC4ACQ34477687-5F4B2714-3F6B-4551-88A2-96B2BB3A8CF7Q34754347-D4CD4173-965B-458D-8DFC-2A18EB5DA56CQ34770066-9401CFB1-C902-4E2A-AEE7-21CF61A4A81CQ35221732-6459B130-E1F3-49D8-B889-434336BCDC0FQ35603131-F547BC13-B816-4686-AE97-113740E4D770Q35615295-140AED43-42A0-42BC-BD48-B53A5CCF1431Q35770325-19761C39-56BC-4FB0-B159-0B14E2BDC5A9Q35979112-CFFF9ED9-7592-4A80-AF7E-2799BB10E55DQ36200301-D66419FA-A88E-45FB-895B-59F6F444624EQ36362670-E4A76D7F-4BB3-42DE-8DC6-034A8FE3A76DQ36366222-3B54115A-0348-44D9-A666-EEAC906EB165Q36368364-9AEDBD80-5E8F-41F9-BCB6-FAA3B622B17EQ36431400-84294C6C-716F-409B-9EEA-718164ED334AQ36617463-DF0CC621-7738-4B5E-BC79-D373F30C5BF4Q37172099-D077695B-464C-4BB1-A69D-B854B2F6BC56Q37176607-2FEFEBA5-4217-4679-AD75-7E9A2BCF9DEDQ37229490-A65D3E17-B55A-43A7-BB7C-91BB2904D2E8Q37414728-8ED6A7FB-E08C-42B7-A0C9-71D14632522AQ38448761-C7A227D9-4899-4F0F-B6D2-2D6398C5F714Q40047932-ADC0A058-5C84-4B7B-AF3D-FEB050FF4471Q40928716-4C8F516A-D7B9-46FE-9B13-903A84BECBE8Q41026682-DCB8C9D5-E384-4AE0-9AF5-2F42F3C0013AQ41253040-1232B634-D070-4AB8-AFD4-765AA446C133Q42452613-5D288A55-85D3-40EA-93B7-3040F6C82AB2Q43450149-34E77F9D-2D05-4501-98F1-F15B5A41AA7EQ44249232-9DBDD446-41DB-4A74-803E-6CA69738CE0EQ47727042-9210D98A-4333-4933-BE53-F391DF6DDD82Q48010302-4E12C7BD-1792-47BD-B10E-1E0B35B14A21Q52863553-38BE1473-2FAF-4953-AD03-3ECB2002B4C6Q57996111-50B36A9C-ADE3-4DE0-BDD5-1E16349A12ECQ58420548-795D87BA-79D8-4482-9907-5BF3CCB98739Q58765130-F2AE5260-2121-4906-BEC3-13AE30D7D2B8
P2860
Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Analysis of MHC class I and II ...... nd malignant cervical lesions.
@ast
Analysis of MHC class I and II ...... nd malignant cervical lesions.
@en
type
label
Analysis of MHC class I and II ...... nd malignant cervical lesions.
@ast
Analysis of MHC class I and II ...... nd malignant cervical lesions.
@en
prefLabel
Analysis of MHC class I and II ...... nd malignant cervical lesions.
@ast
Analysis of MHC class I and II ...... nd malignant cervical lesions.
@en
P2093
P2860
P356
P1476
Analysis of MHC class I and II ...... nd malignant cervical lesions.
@en
P2093
Helmerhorst T
Kenemans P
Snijders PJ
Uyterlinde A
Walboomers JM
van den Brule AJ
P2860
P2888
P304
P356
10.1038/BJC.1993.254
P407
P577
1993-06-01T00:00:00Z
P5875
P6179
1047660767